CD47 and neoplasm: Future progress in precision therapy is likely to rely on the development of combination immunotherapies such as CD47/PD-1 dual blockade and TGF-β trap proteins 36 alongside strategies aimed at reprogramming the tumor microenvironment, including metabolic interventions targeting TDO2 and IDO1 24.